Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid eye drops Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 18, 2026, 9:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Dropless vs. Standard Drops Contralateral Eye Study

NCT02515045
View directory record Official record
Conditions
Cataract
Interventions
TriMoxiVanc, Moxifloxacin HCl 0.5%, Ilevro, Prednisolone acetate 1%
Drug
Lead sponsor
Carolina Eyecare Physicians, LLC
Other
Eligibility
50 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Bloomington, Minnesota • Stillwater, Minnesota • Garden City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

NCT01010633
View directory record Official record
Conditions
Inflammation, Pain
Interventions
Vehicle of Loteprednol Etabonate, Loteprednol Etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

NCT03098953
View directory record Official record
Conditions
Healthy
Interventions
Loteprednol Etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Inglewood, California
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 18, 2026, 9:04 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 18, 2026, 9:04 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

NCT02030990
View directory record Official record
Conditions
Corneal Opacity
Interventions
Mitomycin-C, Fluorometholone 1% topical ocular steroid
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional

Tolerability Comparison of Flarex to Lotemax SM

NCT07588074
View directory record Official record
Conditions
Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications, Kerato Conjunctivitis Sicca, Dry Eye Syndromes, Postoperative Complications
Interventions
Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 18, 2026, 9:04 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

NCT05116345
View directory record Official record
Conditions
Glaucoma Following Surgery
Interventions
DEXTENZA, Topical Dexamethasone
Drug
Lead sponsor
Brian Jerkins, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 18, 2026, 9:04 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

NCT02547623
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone, Prednisolone
Drug
Lead sponsor
ICON Bioscience Inc
Industry
Eligibility
40 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Glendora, California • Hemet, California • Laguna Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 18, 2026, 9:04 AM EDT
Completed No phase listed Observational Results available

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

NCT01344226
View directory record Official record
Conditions
Pseudophakia, Inflammation
Interventions
loteprednol 0.5% ophthalmic solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Independence, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

NCT04781335
View directory record Official record
Conditions
Cataract
Interventions
Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Drug
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
40 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 3 Interventional

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte

NCT00198523
View directory record Official record
Conditions
Eye Infections, Postoperative Complications
Interventions
Prednisolone and Tobramycin, Prednisolone
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Great Bend, Kansas • Boston, Massachusetts • Saint Joseph, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 18, 2026, 9:04 AM EDT
Terminated Phase 4 Interventional

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NCT04687800
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Cathleen McCabe MD
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 18, 2026, 9:04 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery

NCT04281862
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244
View directory record Official record
Conditions
Blepharitis
Interventions
Tobradex ST, Azasite
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

NCT04184999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
SR Cornea Consultants
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sycamore, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

NCT01736527
View directory record Official record
Conditions
Pharmacokinetics
Interventions
LE Gel
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Systane Ultra Versus Maxidex Versus Saline

NCT01775540
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Systane Ultra, Saline solution, Maxidex
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 18, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

NCT00576251
View directory record Official record
Conditions
Ocular Inflammation Associated With Blepharaconjunctivitis
Interventions
Tobramycin 0.3%/Dexamethasone 0.05%, TOBRADEX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 18, 2026, 9:04 AM EDT